Related Experiment Video
Updated: Jun 21, 2026

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
Published on: June 10, 2025
Relationship of hemoglobin A1C and mortality in heart failure patients with diabetes
David Aguilar1, Biykem Bozkurt, Kumudha Ramasubbu
1Winters Center for Heart Failure Research and Section of Cardiology, Department of Medicine, Baylor College of Medicine, 1709 Dryden Street-BCM 620, Suite 500, Box 13, Houston, Texas 77030, USA. daguilar@bcm.edu
Insights
Glycosylated hemoglobin (HbA1C) levels show a U-shaped association with mortality in diabetic patients with heart failure (HF). Optimal outcomes were observed with modest glucose control, suggesting a need for personalized treatment goals.
Area of Science:
- Cardiology
- Endocrinology
- Geriatrics
Background:
- Diabetes mellitus and heart failure (HF) frequently coexist.
- Previous research on the association between glycosylated hemoglobin (HbA1C) and adverse outcomes in diabetic patients with HF has yielded inconsistent results.
- This study addresses the limited and conflicting data by examining HbA1C's impact on mortality and HF hospitalizations.
Purpose of the Study:
- To investigate the relationship between glycosylated hemoglobin (HbA1C) levels and adverse clinical outcomes in a cohort of diabetic patients with established heart failure (HF).
- To determine if specific HbA1C ranges are associated with increased risk of death or HF hospitalization.
- To identify potential optimal glycemic control targets for patients with both diabetes and HF.
Main Methods:
- A retrospective analysis was conducted on a national cohort of 5,815 veterans diagnosed with both HF and diabetes.
- Patients were stratified into quintiles (Q1-Q5) based on their HbA1C levels.
- The study assessed the association between HbA1C quintiles and the risk of all-cause mortality and HF hospitalization over a 2-year follow-up period, with adjustments for confounders.
Main Results:
- Mortality rates at 2 years showed a U-shaped pattern across HbA1C quintiles: Q1 (≤6.4%) 25%, Q2 (6.4%-7.1%) 23%, Q3 (7.1%-7.8%) 17.7%, Q4 (7.8%-9.0%) 22.5%, and Q5 (>9.0%) 23.2%.
- The middle quintile (Q3, HbA1C 7.1%-7.8%) demonstrated significantly reduced mortality compared to the lowest quintile (Q1) after adjusting for confounders (aHR: 0.73; 95% CI: 0.61-0.88; p=0.001).
- HF hospitalization rates increased with higher HbA1C quintiles, but this trend was not statistically significant after adjusting for confounders.
Conclusions:
- The association between HbA1C and mortality in diabetic patients with HF exhibits a U-shaped curve.
- The lowest risk of death was observed in patients with modest glycemic control, specifically HbA1C levels between 7.1% and 7.8%.
- Further prospective research is warranted to establish precise optimal glycemic control targets for this patient population.
Objectives:
This study was designed to examine the relationship between glycosylated hemoglobin (HbA1C) and adverse outcomes in diabetic patients with established heart failure (HF).
Background:
Despite the common coexistence of diabetes and HF, previous studies examining the association between HbA1C and outcomes in this population have been limited and have reported discrepant results.
Methods:
We assessed the association between increasing quintiles (Q1 to Q5) of HbA1C and risk of death or risk of HF hospitalization by conducting a retrospective study in a national cohort of 5,815 veterans with HF and diabetes treated in ambulatory clinics at Veterans Affairs medical centers.
Results:
At 2 years of follow-up, death occurred in 25% of patients in Q1 (HbA1C < or =6.4%), 23% in Q2 (6.4% < HbA1c < or =7.1%), 17.7% in Q3 (7.1% < HbA1c < or =7.8%), 22.5% in Q4 (7.8% < HbA1c < or =9.0%), and 23.2% in Q5 (HbA1c >9.0%). After adjustment for potential confounders, the middle quintile (Q3) had reduced mortality when compared with the lowest quintile (risk-adjusted hazard ratio: 0.73, 95% confidence interval: 0.61 to 0.88, p = 0.001). Hospitalization rates for HF at 2 years increased with increasing quintiles of HbA1C (Q1: 13.3%, Q2: 13.1%, Q3: 15.5%, Q4: 16.4%, and Q5: 18.2%), but this association was not statistically significant when adjusted for potential confounders.
Conclusions:
The association between mortality and HbA1C in diabetic patients with HF appears U-shaped, with the lowest risk of death in those patients with modest glucose control (7.1% < HbA1C < or =7.8%). Future prospective studies are necessary to define optimal treatment goals in these patients.
Related Concept Videos
Hyperglycemia
Diabetic Nephropathy
Diabetes: Symptoms, Diagnosis, and Complications
Heart Failure V: Medical Management
Complications of Diabetes Mellitus
Diabetic Retinopathy